New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

PDS Biotechnology Corporation

Contributing Author

Recent Articles by PDS Biotechnology Corporation

Sep-18	PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population PDSB GlobeNewswire
Sep-02	PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PDSB GlobeNewswire
Aug-25	PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer PDSB GlobeNewswire
Aug-13	PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update PDSB GlobeNewswire
Aug-06	PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results PDSB GlobeNewswire
Jul-10	PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results PDSB GlobeNewswire
Jun-09	PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC PDSB GlobeNewswire
Jun-02	PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-22	PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-20	PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase PDSB GlobeNewswire
May-14	PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update PDSB GlobeNewswire
May-09	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDSB GlobeNewswire
May-08	PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting PDSB GlobeNewswire
May-07	PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results PDSB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.